Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - USP33||cholangiocarcinoma||predicted - sensitive||Pemigatinib||Case Reports/Case Series||Actionable||In a Phase I trial (FIGHT-101), Pemazyre (pemigatinib) treatment in a cholangiocarcinoma patient harboring FGFR2-USP33 led to a partial response that was maintained for 10.7 months, followed by disease progression, however, patient continued on Pemazyre (pemigatinib) treatment for over 12 months further, due to lack of alternative treatment options (PMID: 35176457; NCT02393248).||35176457|